<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930498</url>
  </required_header>
  <id_info>
    <org_study_id>High-risk rNPC-JS001</org_study_id>
    <nct_id>NCT03930498</nct_id>
  </id_info>
  <brief_title>Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>PD-1 Antibody Combined With Chemotherapy in High-risk Recurrent Nasopharyngeal Carcinoma: a Prospective, Open, Single-arm Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to
      evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk
      recurrent nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days)</time_frame>
    <description>Patient's short-term effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days)</time_frame>
    <description>Patient's short-term effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>From date of recruitment to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>From date of recruitment to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>Evaluating with CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: EuroQoL 5 dimension</measure>
    <time_frame>through whole study, an average of 3 years</time_frame>
    <description>Evaluating with questionnaire of EuroQoL 5 dimension, 5 level health state utility index (EQ-5D-5L)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PD-1 antibody plus chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 blocking antibody</intervention_name>
    <description>Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.</description>
    <arm_group_label>PD-1 antibody plus chemoradiotherapy</arm_group_label>
    <other_name>JS001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Cisplatin and Gemcitabine</description>
    <arm_group_label>PD-1 antibody plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>IMRT 60-66Gy, 1.8-2.0Gy/f/day</description>
    <arm_group_label>PD-1 antibody plus chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as local recurrence ± regional recurrence after ≥1 year of radical
             treatment;

          -  Not suitable for surgery;

          -  Newly histologic diagnosis of NPC (WHO II/III);

          -  Clinical stage rII-IVa (AJCC/UICC 8th);

          -  ECOG 0-1 point;

          -  PRANCIS score &gt; 252 points;

          -  No treatment to rNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;

          -  No contraindications to immunotherapy or chemoradiotherapy;

          -  Adequate marrow function: WBC count ≥ 3×10E9/L, NE count ≥ 1.5×10E9/L, HGB ≥ 90g/L,
             PLT count ≥ 100×10E9/L;

          -  Adequate liver function: ALT/AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;

          -  Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥
             60ml/min (Cockcroft-Gault formula);

          -  Take effective contraceptions during and two months after treatment;

          -  Patients must be informed of the investigational nature of this study and give written
             informed consent.

        Exclusion Criteria:

          -  Have recurrence with local necrosis;

          -  Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;

          -  Unexplained fever &gt; 38.5 ℃, except for tumor fever;

          -  Treated with ≥ 5 days antibiotics one month before enrollment;

          -  Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis,
             nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy);

          -  Have a known history of human immunodeficiency virus (HIV), active Hepatitis B
             (HBV-DNA ≥10E3copiers/ml) or hepatitis C virus (HCV) antibody positive;

          -  Have previously treated with PD-1 antibody or other immunotherapy for PD-1/PD-L1
             pathway;

          -  Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial
             -infarction within 1 year, or clinically meaningful arrhythmia that requires
             treatment;

          -  Have known allergy to large molecule protein products or any compound of study
             therapy;

          -  Pregnant or breastfeeding;

          -  Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical
             cancer, and papillary thyroid carcinoma;

          -  Have received a live vaccine within 30 days of planned start of study therapy Has
             psychiatric drug or substance abuse disorders that would interfere with cooperation
             with the requirements of the trial;

          -  Any other condition, including mental illness or domestic/social factors, deemed by
             the investigator to be likely to interfere with a patient's ability to sign informed
             consent, cooperate and participate in the study, or interferes with the interpretation
             of the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong Zhao, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingjing Miao, M.D</last_name>
    <phone>02087342638</phone>
    <email>miaojj1@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chong Zhao, M.D</last_name>
      <phone>+86-13902206160</phone>
      <email>zhaochong@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jingjing Miao, M.D</last_name>
      <phone>02087342638</phone>
      <email>miaojj@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Sun Yat-sen University Cancer Center</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>PD-1 antibody</keyword>
  <keyword>Intensity-modulated Radiation Therapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Adverse effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

